{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:43Z","timestamp":1789726423791,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["21ZR1413500"],"award-info":[{"award-number":["21ZR1413500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200393"],"award-info":[{"award-number":["82200393"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200297"],"award-info":[{"award-number":["82200297"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the real\u2010world efficacy and safety of low\u2010dose (2.5\u2009mg) mavacamten initiation in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>This single\u2010center observational study (Zhongshan Hospital, China; Oct 2024\u2013Apr 2025) enrolled 72 symptomatic oHCM patients (NYHA II\/III, LVEF \u2265\u200955%, resting\/Valsalva\u2010provoked LVOT gradient [LVOTG] \u2265\u200930\u2009mmHg). All patients initiated mavacamten 2.5\u2009mg once daily. Doses were adjusted at Weeks 4, 8, and 12 based on LVEF and LVOTG. Primary outcomes were changes in resting\/provoked LVOTG, NT\u2010proBNP, and NYHA class at Week 12. Safety outcomes included LVEF &lt;\u200950%, cardiac hospitalization, and death.<\/jats:p>\n                    <jats:p>\n                      Significant reductions from baseline to Week 12 were observed: Resting LVOTG (52.4 \u00b1 28.7 to 32.1 \u00b1 23.1\u2009mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), Valsalva\u2010provoked LVOTG (74.1 \u00b1 24.4 to 48.7 \u00b1 25.4\u2009mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), NT\u2010proBNP (1102.7 \u00b1 1114.9 to 320.2 \u00b1 406.2\u2009pg\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). LVEF remained stable. NYHA class improved by \u2265\u20091 class in 83.3% (60\/72) of patients.\n                    <\/jats:p>\n                    <jats:p>\n                      Subgroup analyses revealed significantly greater LVOTG reductions in patients with classic HCM (vs. apical HCM,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and high baseline resting LVOTG (\u2265\u200950\u2009mmHg vs. &lt;\u200950\u2009mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001\/\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04). NYHA improvement was consistent across subgroups.\n                    <\/jats:p>\n                    <jats:p>\n                      Twenty\u2010two patients escalated to 5\u2009mg at Week 12, achieving further significant LVOTG reductions (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), particularly in apical HCM and high\u2010baseline\u2010gradient subgroups, with stable LVEF.\n                    <\/jats:p>\n                    <jats:p>No safety events occurred (LVEF &lt;\u200950%, arrhythmias, hospitalization, and death). Four patients reported transient minor adverse events (dizziness, nausea, and fatigue).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this first Chinese real\u2010world study, initiating mavacamten at 2.5\u2009mg significantly improved haemodynamics (LVOTG), biomarkers (NT\u2010proBNP), and functional status (NYHA) in oHCM patients over 12 weeks with an excellent safety profile. Greater haemodynamic efficacy was observed in classic HCM and high\u2010baseline\u2010gradient patients. Escalation to 5\u2009mg provided additional benefit. Mavacamten is an effective and safe therapy for oHCM in this Asian population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/cdr\/5690104","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:51:53Z","timestamp":1768391513000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low\u2010Dose Mavacamten Initiation in Obstructive Hypertrophic Cardiomyopathy: A Real\u2010World Study in China"],"prefix":"10.1155","volume":"2026","author":[{"given":"Wenlong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-6641","authenticated-orcid":false,"given":"Rebecca Suchi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-8828","authenticated-orcid":false,"given":"Yin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jixiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-3692","authenticated-orcid":false,"given":"Juying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9360-7332","authenticated-orcid":false,"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-6553","authenticated-orcid":false,"given":"Shuning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_2_10_1_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032522"},{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2024.07.013"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.002"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.002"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077274"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad637"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo7622"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-022-00093-x"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00798-4"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3758.2017.12.005"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2018.01.022"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.6.691"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01129-1"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2024.0443"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-24-0501"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069378"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052359"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015294"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2022.11.013"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.4172\/2329-9126.1000161"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-023-02328-8"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12968-020-00623-1"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cdr\/5690104","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/cdr\/5690104","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/cdr\/5690104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T02:54:40Z","timestamp":1773024880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/cdr\/5690104"}},"subtitle":[],"editor":[{"given":"Baohui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/cdr\/5690104"],"URL":"https:\/\/doi.org\/10.1155\/cdr\/5690104","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5690104"}}